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InTRoduCTIon
Pachyonychia congenita (PC) describes a group 
of rare autosomal dominant skin disorders character-
ized predominantly by dystrophic, thickened nails, 
and painful and highly debilitating palmoplantar hy-
perkeratosis (1,2). It is caused by heterozygous mu-
tations in any of the genes encoding the differentia-
tion-specific keratins KRT6A, KRT6B, KRT16, or KRT17 
(1-4). PC was historically classified into at least two 
subtypes according to the clinical features: PC type 
1 (MIM #167200, PC-1, or Jadassohn-Lewandowsky 
syndrome), the more common variant, is character-
ized mainly by nail changes, palmoplantar kerato-
derma (PPK), follicular keratosis and oral leukokerato-
sis, while PC type 2 (MIM #167210, PC-2, or Jackson-
Lawler syndrome) includes the features of PC-1 plus 
natal teeth, epidermal inclusion cysts, pilosebaceous 
cysts such as steatocystomas and vellus hair cysts, 
and hair abnormalities, including alopecia, pili torti 
(twisted hair) and unruly hair (1,2). A third variant, 
PC tarda, has also been described and is character-
ized by a later onset that ranges from late childhood 
to middle age (5). Pathogenic mutations in the genes 
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SuMMARY Pachyonychia congenita (PC) is a rare genodermatosis 
caused by mutations in any of the four genes KRT6A, KRT6B, KRT16, or 
KRT17, which can lead to dystrophic, thickened nails and focal palmo-
plantar keratoderma, among other manifestations. Although classically 
subdivided into two major variants, PC-1 (Jadassohn-Lewandowski 
syndrome) and PC-2 (Jackson-Lawler syndrome), according to the lo-
calization of the mutations in the KRT6A/KRT16 or KRT6B/KRT17 genes, 
respectively, a classification system based on the mutant gene (PC-
6a, PC-6b, PC-16 and PC-17) has been recently proposed. We report a 
2-year-old female patient with a history of thickened and discolored 
nails, small cystic papulonodules on the central face, dry, unruly and 
curly hair, slight palmoplantar hyperkeratosis, and natal teeth. Both 
her father and paternal grandfather presented onychodystrophy, pal-
moplantar keratoderma, and previous excision of “sebaceous” cysts. 
Molecular genetic analysis of the patient revealed a missense mutation 
(c.1163T>C) in heterozygosity in exon 6 of the KRT17 gene, confirming 
the diagnosis of PC-2 (Jackson-Lawler type), or PC-17. We conclude that 
PC is a relatively easy and consistent clinical diagnosis, but a high index 
of suspicion is required if the diagnosis is to be made correctly. With this 
case, the authors intend to draw attention to this condition and the role 
of the dermatologist in the diagnosis.
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encoding keratin 6A (KRT6A) or its expression partner 
keratin 16 (KRT16) are associated with the PC-1 phe-
notype, whereas mutations in PC-2 occur in KRT6B or 
its expression partner KRT17 (1,2). These keratins are 
constitutively expressed in keratinocytes of the nail, 
palmoplantar skin, mucosa, and hair, leading to the 
manifestations of the disorder at these sites. How-
ever, as a considerable overlap between PC subtypes 
exists and distinct phenotypic differences can occur 
in the same variant (6), a new nomenclature based on 
genotyping has been proposed, as follows: PC-6a, PC-
6b, PC-16 and PC-17 (1,7). 
CASE REPoRT
A 2-year-old female born at term to non consan-
guineous parents was referred to our outpatient clinic 
for evaluation of thickened nails starting at the age of 
3 months. She presented a history of natal teeth (both 
mandibular central incisors), and facial pinhead-sized 
yellowish papules noted at birth, that had slowly 
grown during the first year of age. Physical examina-
tion showed: 1) thickened and discolored nails on all 
of her fingers and toes, 2) multiple small cystic papu-
lonodules measuring 2 to 10 mm in diameter over the 
nose and paranasal area, 3) dry, unruly and curly hair, 
and 4) slight palmoplantar hyperkeratosis (Fig. 1). Cu-
riously, both teeth present at birth were missing in the 
deciduous dentition, which had meanwhile erupted. 
There were no lesions in the mucous membranes, 
hoarseness, follicular keratoses or palmoplantar hy-
perhidrosis. Her father also presented thickening and 
discoloration of nails that improved with age, PPK (Fig. 
2), and reported a history of multiple “sebaceous” cysts 
excised on the trunk. A similar clinical picture was pres-
ent in the paternal grandfather as well. None of the re-
maining features present in the girl were detected in 
her father and grandfather. Mutation analysis revealed 
a missense mutation (c.1163T>C) in heterozygosity in 
exon 6 of the KRT17 gene, resulting in the substitution 
of leucine by proline at codon 388 (p.Leu388Pro), as 
the pathological cause of the disorder in the patient. 
Regular application of 40% urea cream under occlu-
sion was started to soften thickened nails, with some 
clinical improvement. 
dISCuSSIon
According to the new suggestions for nomencla-
ture of PC, our patient fits the PC-17 subtype because 
a mutation in the KRT17 gene (c.1163T>C) was de-
tected. This genetic defect was previously identified 
in another family (3) and seems to include cases of 
natal teeth, as confirmed here. The occurrence of na-
tal teeth was formerly considered diagnostic of PC-2 
but, unfortunately, this feature is not fully penetrant, 
i.e. not all PC-2 patients present with natal teeth (2). 
Additionally, cysts are not specific of PC-2 and can 
also occur in PC-1. These and other reasons justify a 
genotype-based classification instead of the classic 
division into PC-1 and PC-2, based on subtly variable 
phenotypic features.
The majority of keratin mutations are heterozy-
gous missense mutations; in some cases, small in-
frame deletion/insertion mutations have been re-
ported. Most mutations occur in the highly conserved 
helix boundary motifs of the keratin polypeptide, 
located at either the start or the end of the central 
keratin rod domain, and individually known as the 
helix initiation motif and the helix termination motif 
(8). In our patient, a missense mutation affecting the 
KRT17 helix termination motif was identified. In the 
study by Wilson et al. (4) including 90 families with 
PC, approximately half of the kindreds had mutations 
in KRT6A (52%), 28% had mutations in KRT16, 17% in 
KRT17, and 3% of families had mutations in KRT6B. 
The variability of phenotype and incomplete pen-
etrance seen in PC strongly suggest that genetic and/
or environmental modifier effects are modulating the 
genotype-phenotype relationship (2). A strict geno-
type-phenotype correlation between mutations and 
clinical severity has not been established, and mem-
bers of the same family or unrelated patients with the 
same mutation sometimes display different levels of 
severity and different clinical spectra (2). In our pedi-
gree, evident onychodystrophy and natal teeth were 
Figure 1. Clinical appearance of our patient: hypertrophic 
nail dystrophy (pachyonychia) with yellowish discoloration 
on the toenails (a) and fingernails (b,c); small yellow-
whitish cysts on the central face (d); dry, unruly and curly 
hair (e); and absence of both mandibular central incisor 
teeth, the teeth that were present at birth (f ); note distal 
hyperpigmentation of the left thumbnail of the patient’s 
father (f ).
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detected in the girl, but only slight thickening of the 
nail plate and no history of natal teeth were found in 
her father and grandfather. 
The frequency of clinical findings in PC was re-
viewed by Leachman et al. (2) using data from the 
International Pachyonychia Congenita Research Reg-
istry, the National Registry for Ichthyosis and Related 
Disorders, and case studies in the literature. The most 
common (90%-98%) and one of the earliest manifesta-
tions of PC was onychodystrophy, followed by plantar 
pain (91%-96%) and plantar keratoderma (91%-96%), 
which was more pronounced in weight-bearing or 
traumatized areas. Hyperkeratosis was less frequent 
on the palmar surface (60%-80%). Other clinical 
findings were oral leukokeratosis (75%-95%), follicu-
lar keratoses (65%-79%), hyperhidrosis (36%-79%), 
cysts of any type (35%-72%), laryngeal involvement 
or hoarseness (16%-70%), hair abnormalities (26%-
53%), and natal or prenatal teeth (2%-50%), which are 
usually lost within the first few months of life, as ob-
served in our patient. Blistering, hyperkeratosis with 
fissuring, and pain on the palms and soles are the 
main difficulties for many patients with PC. In the ma-
jority of cases (83%), the onset of clinical symptoms 
occurs within the first year of life (2). In the study by 
Eliason et al. (7), although the age of onset varied con-
siderably among patients, a diagnostic triad of toenail 
thickening, plantar keratoderma and plantar pain was 
reported by 97% of individuals with PC by the age of 
10 years. They also observed a higher likelihood of 
oral leukokeratosis in patients harboring KRT6A muta-
tions, and a strong association of natal teeth and cysts 
in carriers of a KRT17 mutation, as confirmed in our 
study. A comprehensive and thorough review of clini-
cal features of PC is available elsewhere (1,2,7).
Diagnosis of PC is based on clinical examination 
and is confirmed by molecular genetic testing. PC 
should be differentiated from other conditions char-
acterized by nail dystrophy (e.g., traumatic thicken-
ing of nails, congenital onychogryphosis, onycho-
mycosis, twenty nail dystrophy), focal PPK associated 
with oral leukokeratosis, focal non-epidermolytic 
PPK, striate PPK or other PPKs, psoriasis, and pityriasis 
rubra pilaris. Oral leukokeratosis may be mistaken for 
Candida albicans (thrush), leukoplakia and/or white 
sponge nevus if no other findings of PC are appar-
ent. PC should be also distinguished from the curly 
hair-acral keratoderma-caries syndrome, Clouston 
syndrome, and congenital dyskeratosis (9). Most of 
these conditions lack the features of PC or have dis-
tinctive characteristics, making them easy to recog-
nize, if detailed history and physical examination are 
performed. However, biopsy, microbiological studies, 
genetic testing and others may be necessary for a 
conclusive diagnosis.
Like most genodermatoses, no specific treat-
ment or cure is known for PC-2. Therapy is gener-
ally directed towards symptomatic improvement of 
the most troublesome manifestations of the disease 
(10). Mechanical thinning of thick nails and calluses 
with a variety of hand tools such as pumice stones, 
emery boards, paring knives, razor blades, clippers, 
curettes, rasps, and files may be helpful. Some pa-
tients use electrical tools, such as grinders, polishers, 
and sanders, to reduce thickened nails. Softening of 
the nails and calluses can also be achieved with over-
night application of topical keratolytics under occlu-
sion, such as pastes of 20%-40% urea or 15%-20% 
salicylic acid (10). Systemic retinoids make the keratin 
more flexible and less pronounced without complete 
clearing. Although they can be effective in some pa-
tients with PC, treatment is generally unsatisfactory 
(11). Risk/benefit analysis favors lower retinoid doses 
(≤25 mg/d) over a longer time period (>5 months). 
However, many patients discontinue medication 
Figure 2. Clinical appearance of the patient’s father: mild thickening of fingernails more evident in the thumb and index, 
where distal brownish discoloration can also be noted (a); roughness and yellowish discoloration of distal toenails, 
associated with onychomycosis of great toenail (b); and slight plantar hyperkeratosis with fissuring, more prominent on the 
heels (c,d).
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because adverse effects outweigh the benefits (11). In 
last instance, surgical avulsion and matrix destruction 
followed by scarification of the nail bed to prevent re-
growth can be performed. Treatment of hyperhidro-
sis appears to be helpful in decreasing blistering and 
pain and can be achieved with agents such as alumi-
num chloride, oral administration of glycopyrrolate 
or plantar injections of botulinum toxin (10,12). Hick-
erson et al. (10) showed that the macrolide sirolimus 
(rapamycin) selectively blocks K6a expression in hu-
man keratinocytes. The improvement of symptoms 
in PC patients following this treatment, including 
reduction of painful plantar thromboses and kerato-
ses suggests that rapamycin (or rapamycin analogs) 
may be a good future treatment option, particularly 
if topical formulations can be developed to avoid the 
unacceptable gastrointestinal and mucocutaneous 
side effects associated with systemic administration 
(13). Other authors found that simvastatin and other 
statins inhibit K6a promoter activity and K6a protein 
expression, opening the scene for further clinical tri-
als with statins as a possible therapeutic option for 
PC patients (14). Finally, some studies revealed that 
small interfering RNAs (siRNAs) could specifically and 
very potently block expression of mutant K6a in the 
skin and support development of these inhibitors as 
potential therapeutic agents for the treatment of PC 
(15). 
ConCLuSIon
Although PC does not endanger an individual’s 
life, it may significantly impair the quality of life. Un-
derstanding the genetic basis of the disease allows 
better counseling for patients, creates new options 
for suitable therapeutic regimens, and even offers 
hope of curing such type of skin disease by means of 
gene therapy. Diagnosing and managing PC in early 
childhood are critical to help the affected children.
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